{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:52:46Z","timestamp":1767181966654,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"CinnaGen Co","award":["91-107950"],"award-info":[{"award-number":["91-107950"]}]},{"DOI":"10.13039\/501100007103","name":"Semnan University","doi-asserted-by":"publisher","award":["499"],"award-info":[{"award-number":["499"]}],"id":[{"id":"10.13039\/501100007103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.intimp.2018.06.032","type":"journal-article","created":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T15:50:47Z","timestamp":1530978647000},"page":"109-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Neutralizing antibody production against Rebif\u00ae and ReciGen\u00ae in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5197-1139","authenticated-orcid":false,"given":"Mahdieh","family":"Shokrollahi Barough","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fereshteh","family":"Ashtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Sadat Akhavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabiollah","family":"Asghari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghasem","family":"Mosayebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Mirmohammadkhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naser","family":"Kokhaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Bahraminia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arman","family":"Ajami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6544-4209","authenticated-orcid":false,"given":"Parviz","family":"Kokhaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2018.06.032_bb0005","first-page":"24","article-title":"Multiple sclerosis: a study of 318 Iranian cases","volume":"5","author":"Aleyasin","year":"2002","journal-title":"Iran. Med."},{"issue":"6","key":"10.1016\/j.intimp.2018.06.032_bb0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000321649","article-title":"Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time","volume":"64","author":"Sahraian","year":"2010","journal-title":"Eur. Neurol."},{"issue":"8","key":"10.1016\/j.intimp.2018.06.032_bb0015","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S1474-4422(14)70101-2","article-title":"Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging","volume":"13","author":"Ciccarelli","year":"2014","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.intimp.2018.06.032_bb0020","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/acn3.84","article-title":"Immunomodulatory activity of interferon-beta","volume":"1","author":"Kasper","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2018.06.032_bb0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/1756285608095144","article-title":"Review: neutralizing antibodies against interferon-beta","volume":"1","author":"Sorensen","year":"2008","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.intimp.2018.06.032_bb0030","series-title":"Therapeutic Biologic Applications (BLA)","article-title":"Interferon beta-1b product approval information - licensing action 3\/14\/03","author":"U.f.a.d. administration","year":"2014"},{"key":"10.1016\/j.intimp.2018.06.032_bb0035","series-title":"Therapeutic Biologic Applications (BLA)","article-title":"Interferon beta-1a product approval information - licensing action","author":"F.a.d.a. US","year":"2014"},{"volume":"2015","year":"2015","author":"C. Company, Recigen","key":"10.1016\/j.intimp.2018.06.032_bb0040"},{"issue":"11","key":"10.1016\/j.intimp.2018.06.032_bb0045","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1089\/jir.2012.0079","article-title":"Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-beta","volume":"33","author":"Wadhwa","year":"2013","journal-title":"J. Interf. Cytokine Res."},{"issue":"1","key":"10.1016\/j.intimp.2018.06.032_bb0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1191\/1352458503ms889oa","article-title":"A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta","volume":"9","author":"Kob","year":"2003","journal-title":"Mult. Scler."},{"year":"2011","series-title":"Usage and Costs of Treatment with Beta Interferon Among Patients With Multiple Sclerosis in Fars Province","author":"Nikseresht","key":"10.1016\/j.intimp.2018.06.032_bb0055"},{"key":"10.1016\/j.intimp.2018.06.032_bb0060","unstructured":"I. protocols, A549 Supplement Media, 2015. http:\/\/ibrc.ir\/index.aspx?fkeyid=&siteid=1&pageid=931&p=1&showitem=5. (Accessed January 19, 2018)."},{"issue":"2","key":"10.1016\/j.intimp.2018.06.032_bb0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/jir.2008.0043","article-title":"The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels","volume":"29","author":"Grossberg","year":"2009","journal-title":"J. Interf. Cytokine Res."},{"issue":"2","key":"10.1016\/j.intimp.2018.06.032_bb0070","first-page":"62","article-title":"Neutralizing antibodies against interferon-beta","volume":"1","author":"Sorensen","year":"2008","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9139","key":"10.1016\/j.intimp.2018.06.032_bb0075","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2018.06.032_bb0080","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.clineuro.2013.09.024","article-title":"Interferon-beta and disability progression in relapsing-remitting multiple sclerosis","volume":"115","author":"Drulovic","year":"2013","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"9","key":"10.1016\/j.intimp.2018.06.032_bb0085","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1177\/1352458507080468","article-title":"Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study","volume":"13","author":"Boz","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.intimp.2018.06.032_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-014-0215-y","article-title":"Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis","volume":"14","author":"Manceau","year":"2014","journal-title":"BMC Neurol."},{"issue":"6","key":"10.1016\/j.intimp.2018.06.032_bb0095","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1007\/s00415-012-6829-3","article-title":"The impact of neutralizing antibodies on the risk of disease worsening in interferon beta-treated relapsing multiple sclerosis: a 5\u202fyear post-marketing study","volume":"260","author":"Paolicelli","year":"2013","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.intimp.2018.06.032_bb0100","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/bmm.10.81","article-title":"Cytokine patterns after therapy with Avonex(R), Rebif(R), Betaferon(R) and CinnoVex in relapsing-remitting multiple sclerosis in Iranian patients","volume":"4","author":"Arababadi","year":"2010","journal-title":"Biomark. Med"},{"issue":"2","key":"10.1016\/j.intimp.2018.06.032_bb0105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/jnnp.73.2.148","article-title":"Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory","volume":"73","author":"Bertolotto","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2018.06.032_bb0110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jim.2012.11.013","article-title":"Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of measurements in two different laboratories","volume":"388","author":"Shahkarami","year":"2013","journal-title":"J. Immunol. Methods"},{"issue":"12","key":"10.1016\/j.intimp.2018.06.032_bb0115","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3346\/jkms.2013.28.12.1801","article-title":"Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon","volume":"28","author":"Zare","year":"2013","journal-title":"J. Korean Med. Sci."},{"issue":"45","key":"10.1016\/j.intimp.2018.06.032_bb0120","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005337","article-title":"The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients","volume":"95","author":"Wencel-Warot","year":"2016","journal-title":"Medicine"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918302832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918302832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:10:41Z","timestamp":1761585041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576918302832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":24,"alternative-id":["S1567576918302832"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2018.06.032","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralizing antibody production against Rebif\u00ae and ReciGen\u00ae in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2018.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}